These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 37423332)

  • 1. Prognostic Indicators for H3K27M-Mutant Diffuse Midline Glioma: A Population-Based Retrospective Surveillance, Epidemiology, and End Results Database Analysis.
    Adhikari S; Bhutada AS; Ladner L; Cuoco JA; Entwistle JJ; Marvin EA; Rogers CM
    World Neurosurg; 2023 Oct; 178():e113-e121. PubMed ID: 37423332
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differences in survival prognosticators between children and adults with H3K27M-mutant diffuse midline glioma.
    Gong X; Kuang S; Deng D; Wu J; Zhang L; Liu C
    CNS Neurosci Ther; 2023 Dec; 29(12):3863-3875. PubMed ID: 37311690
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radiotherapy plus temozolomide with or without anlotinib in H3K27M-mutant diffuse midline glioma: A retrospective cohort study.
    Liu C; Kuang S; Huang T; Wu J; Zhang L; Gong X
    CNS Neurosci Ther; 2024 Apr; 30(4):e14730. PubMed ID: 38644565
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comprehensive genomic study of 390 H3F3A-mutant pediatric and adult diffuse high-grade gliomas, CNS WHO grade 4.
    Williams EA; Brastianos PK; Wakimoto H; Zolal A; Filbin MG; Cahill DP; Santagata S; Juratli TA
    Acta Neuropathol; 2023 Sep; 146(3):515-525. PubMed ID: 37524847
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characteristics of H3K27M-mutant diffuse gliomas with a non-midline location.
    Guidara S; Seyve A; Poncet D; Leonce C; Bringuier PP; McLeer A; Sturm D; Cartalat S; Picart T; Ferrari A; Hench J; Frank S; Meyronet D; Ducray F; Barritault M
    J Neurooncol; 2024 Sep; 169(2):391-398. PubMed ID: 38937309
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Significance of H3K27M Mutation in "Nonmidline" High-Grade Gliomas of Cerebral Hemispheres.
    La Rocca G; Sabatino G; Altieri R; Signorelli F; Ricciardi L; Gessi M; Della Pepa GM
    World Neurosurg; 2019 Nov; 131():174-176. PubMed ID: 31415896
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clinicopathological characteristics and prognosis of diffuse midline gliomas with histone H3K27M mutation: an analysis of 30 cases].
    Li HN; Shan CG; Fan CZ; Cheng LN; Wu SG; Liu MT; Jiang GY; Li Z
    Zhonghua Bing Li Xue Za Zhi; 2019 Mar; 48(3):192-198. PubMed ID: 30831644
    [No Abstract]   [Full Text] [Related]  

  • 8. Clinicohistoradiological and surgical outcome in diffuse midline glioma.
    Kumar Suman A; Bhattacharjee S; Uppin MS; Fathima ST
    Childs Nerv Syst; 2024 Jan; 40(1):65-71. PubMed ID: 37644138
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Liquid biopsy in H3K27M diffuse midline glioma.
    Patel J; Aittaleb R; Doherty R; Gera A; Lau B; Messinger D; Wadden J; Franson A; Saratsis A; Koschmann C
    Neuro Oncol; 2024 May; 26(Supplement_2):S101-S109. PubMed ID: 38096156
    [TBL] [Abstract][Full Text] [Related]  

  • 10. STAT3 is a biologically relevant therapeutic target in H3K27M-mutant diffuse midline glioma.
    Zhang L; Nesvick CL; Day CA; Choi J; Lu VM; Peterson T; Power EA; Anderson JB; Hamdan FH; Decker PA; Simons R; Welby JP; Siada R; Ge J; Kaptzan T; Johnsen SA; Hinchcliffe EH; Daniels DJ
    Neuro Oncol; 2022 Oct; 24(10):1700-1711. PubMed ID: 35397475
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transcriptomic and epigenetic profiling of 'diffuse midline gliomas, H3 K27M-mutant' discriminate two subgroups based on the type of histone H3 mutated and not supratentorial or infratentorial location.
    Castel D; Philippe C; Kergrohen T; Sill M; Merlevede J; Barret E; Puget S; Sainte-Rose C; Kramm CM; Jones C; Varlet P; Pfister SM; Grill J; Jones DTW; Debily MA
    Acta Neuropathol Commun; 2018 Nov; 6(1):117. PubMed ID: 30396367
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of the H3K27M mutation on survival in pediatric high-grade glioma: a systematic review and meta-analysis.
    Lu VM; Alvi MA; McDonald KL; Daniels DJ
    J Neurosurg Pediatr; 2019 Mar; 23(3):308-316. PubMed ID: 30544362
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted therapy with anlotinib for a H3K27M mutation diffuse midline glioma patient with PDGFR-α mutation: a case report.
    Wang Q; Niu W; Pan H
    Acta Neurochir (Wien); 2022 Aug; 164(8):2063-2066. PubMed ID: 34812950
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adult diffuse intrinsic pontine glioma: clinical, radiological, pathological, molecular features, and treatments of 96 patients.
    Wang Y; Pan C; Xie M; Zuo P; Li X; Gu G; Li T; Jiang Z; Wu Z; Zhang J; Zhang L
    J Neurosurg; 2022 Dec; 137(6):1628-1638. PubMed ID: 35395636
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advanced MR imaging and
    Piccardo A; Tortora D; Mascelli S; Severino M; Piatelli G; Consales A; Pescetto M; Biassoni V; Schiavello E; Massollo M; Verrico A; Milanaccio C; Garrè ML; Rossi A; Morana G
    Eur J Nucl Med Mol Imaging; 2019 Jul; 46(8):1685-1694. PubMed ID: 31030232
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of prognostic markers in diffuse midline gliomas H3K27M-mutant.
    Dufour C; Perbet R; Leblond P; Vasseur R; Stechly L; Pierache A; Reyns N; Touzet G; Le Rhun E; Vinchon M; Maurage CA; Escande F; Renaud F
    Brain Pathol; 2020 Jan; 30(1):179-190. PubMed ID: 31348837
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinico-pathological and molecular characterization of diffuse midline gliomas: is there a prognostic significance?
    Manjunath N; Jha P; Singh J; Raheja A; Kaur K; Suri A; Garg A; Sharma MC; Sarkar C; Mohan M; Mani K; Suri V
    Neurol Sci; 2021 Mar; 42(3):925-934. PubMed ID: 32666407
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Spinal intramedullary H3K27M mutant glioma with vertebral metastasis: a case report.
    Handis C; Tanrıkulu B; Danyeli AE; Özek MM
    Childs Nerv Syst; 2021 Dec; 37(12):3933-3937. PubMed ID: 33742289
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical Findings of Thalamic and Brainstem Glioma Including Diffuse Midline Glioma, H3K27M Mutant:A Clinical Study].
    Kim Y; Kudo T; Tamura K; Sumita K; Kobayashi D; Tanaka Y; Inaji M; Nariai T; Ishii K; Maehara T
    No Shinkei Geka; 2021 Jul; 49(4):901-908. PubMed ID: 34376622
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serial H3K27M cell-free tumor DNA (cf-tDNA) tracking predicts ONC201 treatment response and progression in diffuse midline glioma.
    Cantor E; Wierzbicki K; Tarapore RS; Ravi K; Thomas C; Cartaxo R; Nand Yadav V; Ravindran R; Bruzek AK; Wadden J; John V; May Babila C; Cummings JR; Rahman Kawakibi A; Ji S; Ramos J; Paul A; Walling D; Leonard M; Robertson P; Franson A; Mody R; Garton HJL; Venneti S; Odia Y; Kline C; Vitanza NA; Khatua S; Mueller S; Allen JE; Gardner SL; Koschmann C
    Neuro Oncol; 2022 Aug; 24(8):1366-1374. PubMed ID: 35137228
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.